Investigation of the IL-1 β Genotype and its Levels on Patients Treated with Osteointegrated Dental Implants

Year 2019, , 11 - 15, 30.04.2019

Ferhat Dizen Uzay Görmüş Arzu Ergen Meral Ünür Elif Sinem İplik Bedia Çakmakoğlu , Turgay İsbir

https://doi.org/10.26650/experimed.2019.19002

Abstract

DOI:
10.26650/experimed.2019.19002

Objective: In our study, we aimed to investigate the relationship between the Interleukin-1β (IL-1β) +3953 gene polymorphism, the levels of this interleukin and smoking in osteointegrated dental implant losses.

Materials and Methods: 56 patients with
implants and 238 healthy control subjects were included in this study. PCR and
RFLP methods was used to determine the IL-1β +3953 gene polymorphisms. Serum IL-1β levels were measured using ELISA.

Results: The IL-1β  +3953   CC, TT and CT genotype frequencies for the
controls and study cases were 61.2%, 
10.1% ,43.6%, and 48.2%, 8.9% and 42.9%, respectively. IL-1β  +3953 T allele carriers
increased more in the patient group (51.8%) compared  to the control group (38.8%). These cases
also  had an increased plaque index,
bleeding index, pocket deepness and serum IL-1β levels, but none of them were statistically significant
(p>0.05). Implant losses were more frequent in C allele carriers than in T
allele carriers, but this was not statistically significant (p>0.05) Three
of the five patients that experienced implant loss and  smoked, lost the implant earlier and had a
higher average plaque and bleeding index.

Conclusion: Based on our results, we can suggest
that being an IL-1β positive
genotype and a smoker can have an effect on implant losses. The study group
should be enlarged to comment with statistically significant results.

Cite this article as: Dizen F, Görmüş U,
Ergen A, Ünür M, İplik ES, Çakmakoğlu B, et al. Investigation of the IL-1 β Genotype and its Levels on Patients Treated with Osteointegrated
Dental Implants. Experimed 2019; 9(1): 11-5.

Keywords

IL-1β +3953, Implant, Interleukin, polymorphism

Osteointegre Dental İmplant Tedavisi Gören Hastalarda IL-1 β Genotipi ve Seviyelerinin İncelenmesi

Abstract

DOI:
10.26650/experimed.2019.19002

Amaç: Çalışmamızda osteointegre dental
implant kayıplarında interlökin-1β (IL-1β) +3953 gen
polimorfizminin serum interlökin düzeyleri ve sigara içimiyle ilişkisini araştırmayı
amaçladık.

Yöntemler: İmplant yapılan 56 olgu ve 238
sağlıklı kontrol öalışmaya dahil edilmiştir. IL-1β +3953 polimorfizmi, polimeraz zincirleme reaksiyonu ve restriksiyon
fragmanı uzunluk polimorfizmi yöntemleri kullanılarak tayin edilmiştir. Serum örneklerinde
IL-1β seviyesi ELISA yöntemi ile
saptanmıştır.

Bulgular: IL-1β  +3953 polimorfizmi; CC, TT
ve CT genotip frekansları kontrol ve hasta grubu için sırasıyla 61.2%,  10.1% , 43.6%, ve 48.2%, 8.9% ve 42.9% olarak
bulunmuştur. IL-1β +3953 T
alleli taşıyanların hastalarda (51.8%) kontrol grubuna (38.8%) göre daha yüksek
bulunmuştur ve bu kişilerde plak indeksi, kanama indeksi, cep derinliği ve
serum IL-1β düzeylerinin
arttığı, sigara içme ve implant kaybı oranının yükseldiği fakat istatistiksel
anlamlılığa ulaşmadığı tespit edilmiştir (p>0,05). İmplant kaybında, C
alleli taşıyanlarda T alleli taşıyanlara göre daha anlamlı bulunmasına rağmen
istatistiksel olarak anlamlı olmadığı görülmüştür (p>0,05).  İmplant kaybı olan beş hastanın üçünde IL-1β pozitif olduğu, hepsinin sigara kullandığı, implantların erken dönemde
kaybedildiği, plak ve kanama indekslerinin ortalama değerlerden yüksek olduğu
ve cep derinliklerinin normal sınırlar arasında olduğu görülmüştür.

Sonuç: Sonuç olarak implant kaybında IL-1β pozitif genotipe sahip olma ve sigara içiminin önemli bir etken
olduğu izlenimi edinilmiş ancak olgu sayısının arttırılmasıyla istatistiksel
anlamlılığa ulaşılabileceği sonucuna ulaşılmıştır.

Cite this article as: Dizen F, Görmüş U,
Ergen A, Ünür M, İplik ES, Çakmakoğlu B, et al. Investigation of the IL-1 β Genotype and its Levels on Patients Treated with Osteointegrated
Dental Implants. Experimed 2019; 9(1): 11-5.

Keywords

IL-1β +3953, implant, interlökin, polimorfizm

References

• 1. Mombelli A, Van Oosten MA, Schurch E, et al. The microbiota associated with successful or failing osseointegrated titanium implants. Oral Microbiol Immunol 1987; 2: 145-51. 2. Behneke A, Behneke N, d’Hoedt B. A 5-year longitudinal study of the clinical effectiveness of ITI solid-screw implants in the treatment of mandibular edentulism. Int J Oral Maxillofac Implants 2002; 7: 799-810. 3. Ferrigno N, Laureti M, Fanali S, et al. A long-term follow-up study of non-submerged ITI implants in the treatment of totally edentulous jaws. Part I: Ten-year life table analysis of a prospective multicenter study with 1286 implants. Clin Oral Implants Res 2002; 13: 260-73. 4. Lemmerman KJ, Lemmerman NE. Osseointegrated dental implants in private practice: a long-term case series study. J Periodontol 2005; 76: 310-9. 5. Brägger U. Use of radiographs in evaluating success, stability and failure in implant dentistry. Periodontol 2000 1998; 17: 77-88. 6. Lindhe J, Berglundh T, Ericsson I, et al. Experimental breakdown of peri-implant and periodontal tissues. A study in the beagle dog. Clin Oral Implants Res 1992; 3: 9-16. 7. Esposito M, Hirsch JM, Lekholm U, et al. Biological factors contributing to failures of osseointegrated oral implants. (II). Etiopathogenesis. Eur J Oral Sci 1998; 106: 721-64. 8. Santamaria P, Gehrz RC, Bryan MK, et al. Involvement of class II MHC molecules in the LPS-induction of IL-1/TNF secretions by human monocytes. Quantitative differences at the polymorphic level. J Immunol 1989; 143: 913-22. 9. De Boever AL, De Boever JA. Early colonization of non-submerged dental implants in patients with a history of advanced aggressive periodontitis. Clin Oral Implants Res 2006; 17: 8-17. 10. Greenstein G, Hart TC. Clinical utility of a genetic susceptibility test for severe chronic periodontitis: a critical evaluation. J Am Dent Assoc 2002; 133: 452-9. 11. McGuire MK, Nunn ME. Prognosis versus actual outcome. IV. The effectiveness of clinical parameters and IL-1 genotype in accurately predicting prognoses and tooth survival. J Periodont 1997; 70: 49-56. 12. Pociot F, Molvig J, Wogensen L, et al. A TaqI polymorphism in the human interleukin-1b (IL-1b) gene correlates with IL-1b secretion in vitro. Eur J Clin Invest 1992; 22: 396-402. 13. Spiekermann H, Jansen VK, Richter EJ. A 10-year follow-up study of IMZ and TPS implants in the edentulous mandible using bar-retained overdentures. Int J Oral Maxillofac Implants 1995; 10: 231-43. 14. Branemark PI, Adell R, Albrektsson T, et al. Osseointegrated titanium fixtures in the treatment of edentulousness. Biomaterials 1983; 4: 25-8. 15. Laine ML, Leonhardt A, Roos-Jansaker A-M, et al. IL-1RN gene polymorphism is associated with peri-implantitis. Clin. Oral Impl Res 2006; 17: 380-5. 16. Kao RT, Curtis DA, Richards DW, et al. Increased interleukin-1 beta in the crevicular fluid of diseased implants. Int J Oral Maxillofac Implants 1995; 10: 696-701. 17. Panagakos FS, Aboyoussef H, Dondero R, et al. Detection and measurement of inflammatory cytokines in implant crevicular fluid: a pilot study. Int J Oral Maxillofac Implants 1996; 11: 794-9. 18. Dinarello CA. The biological properties of interleukin-1. Eur Cytokine Network 1994;5:517-531. 19. Gemmell E, Marshall RI and Seymour GJ: Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease. Periodontology 2000 1997; 14: 112-43. 20. Kornman KS, Crane A, Wang HY, et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997; 24: 72-7. 21. Edwards RK, Ferguson RJ, Duff P. The Interleukin-1b +3953 Single Nucleotide Polymorphism: Cervical Protein Concentration and Preterm Delivery Risk American. J Reprod Immunol 2006; 55: 259-64. 22. Pietruski JK, Pietruska MD, Stokowska W, et al. Serum levels of interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8) in patients treated with dental implants. Rocz Akad Med Bialymst 2001; 46: 28-37. 23. Sakellari D, Koukoudetsos S, Arsenakis M, et al. Prevalence of IL-1A and IL-1B polymorphisms in a Greek population. J Clin Periodontol 2003; 30: 35-41. 24. Rogers MA, Figliomeni L, Baluchova K, et al. Do interleukin-1 polymorphisms predict the development of periodontitis or the success of dental implants? J Periodontal Res 2002; 37: 37-41. 25. Feloutzis A, Lang NP, Tonetti MS, et al. IL-1 gene polymorphism and smoking as risk factors for peri-implant bone loss in a well-maintained population. Clin Oral Implants Res 2003; 14: 10-17. 26. McGuire MK, Nunn ME. Prognosis versus actual outcome. IV. The effectiveness of clinical parameters and IL-1 genotype in accurately predicting prognoses and tooth survival. J Periodontol 1999; 70: 49-56. 27. Kornman KS: Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. Am J Clin Nutr 2006; 83: 475S-83S. 28. Tonetti MS. Risk factors for osseodisintegration. Periodontol 2000 1998; 17: 55-62. 29. Lindquist LW, Carlsson GE, Jemt T. Association between marginal bone loss around osseointegrated mandibular implants and smoking habits: a 10-year follow-up study. J Dent Res 1997; 76: 1667-74.